AMRX vs. ROIV, RVMD, BPMC, BBIO, ELAN, VRNA, TLX, GRFS, TGTX, and LEGN
Should you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Grifols (GRFS), TG Therapeutics (TGTX), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.
Amneal Pharmaceuticals vs.
Roivant Sciences (NASDAQ:ROIV) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking.
Roivant Sciences received 36 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 95.24% of users gave Amneal Pharmaceuticals an outperform vote while only 78.87% of users gave Roivant Sciences an outperform vote.
64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Roivant Sciences has higher earnings, but lower revenue than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Roivant Sciences presently has a consensus target price of $17.50, suggesting a potential upside of 59.38%. Amneal Pharmaceuticals has a consensus target price of $11.50, suggesting a potential upside of 56.04%. Given Roivant Sciences' higher probable upside, research analysts plainly believe Roivant Sciences is more favorable than Amneal Pharmaceuticals.
In the previous week, Roivant Sciences had 11 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Roivant Sciences and 8 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.44 beat Roivant Sciences' score of 0.35 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.
Roivant Sciences has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.
Amneal Pharmaceuticals has a net margin of -6.88% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Amneal Pharmaceuticals' return on equity.
Summary
Roivant Sciences and Amneal Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Amneal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amneal Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AMRX) was last updated on 5/31/2025 by MarketBeat.com Staff
Buy AMRX Stock Free AMRX Stock Alerts